ResurFX(TM) Fractional Non-Ablative Laser Module to Be Unveiled by Lumenis(R) at the American Academy of Dermatology's Annual Meeting

YOKNEAM, ISRAEL, Mar 02 (Marketwire) --
At the 71st Annual Meeting of the American Academy of Dermatology (AAD),
the ResurFX* module will be launched for international sales by Lumenis
Ltd., the world's largest developer and manufacturer of advanced medical
lasers for aesthetic, surgical, and ophthalmic applications. ResurFX is
an affordable module for the M22(TM) device, the company's
multi-application, multi-technology platform. The 1565nm fiber laser
energy is delivered by patent-pending CoolScan(TM) scanner to perform
non-sequential scanning to maximize efficacy and reproducible results.
The module extends the ability of Lumenis' gold-standard M22 to perform
non-ablative skin resurfacing and treat some of the most common aesthetic
skin concerns including acne and surgical scars, skin discoloration,
periorbital wrinkles and stretch marks. Although the ResurFX module has
not yet been FDA cleared, international physicians may see it on display
along with Lumenis' broad portfolio of medical lasers for body shaping,
tattoo removal, hair removal, scar revision and IPL skin rejuvenation at
booth #2035 throughout the AAD meeting, which runs from March 1 to 5 in
Miami Beach.

"The new ResurFX module for M22 is a true non-ablative fractional fiber
laser technology. It uses a unique algorithm to apply micro-beams of
1565nm laser energy in a non-sequential pattern to increase patient
comfort and minimize non-specific thermal damage using the
'cool-scanning' technology pioneered by Lumenis. With over 600 parameter
combinations, ResurFX gives me the greatest possible flexibility in
treating a wide range of conditions," said Dr. Mitchel P. Goldman, M.D.,
principle investigator for ResurFX, Volunteer Clinical Professor of
Dermatology, University of California, San Diego and Medical Director,
Dermatology/Cosmetic Laser Associates of La Jolla, Inc.

"Lumenis invented, advanced, and perfected Intense Pulsed Light (IPL)
technology with both doctors and patients in mind, and we are committed
to remaining at the forefront of innovation so that we can solidify our
45 year legacy as the partner of choice in medical devices," said Roy
Ramati, Vice President & General Manager of the Aesthetic Strategic
Business Unit at Lumenis. "We work with a broad network of leading
physicians worldwide to develop practical solutions to help our customers
meet the real-world needs of their patients. The M22 is the only
multi-application, multi-technology platform that combines three
proprietary, robust technologies offering more than 40 indications for
use in one platform: Intense Pulsed Light with Optimal Pulse
Technology(TM), Multi-spot Nd:YAG and now ResurFX for a complete
aesthetic workstation."

Lumenis will also have a variety of educational events taking place at
its booth throughout the AAD conference.

Lumenis at the AAD 2013

Educational Activities at Booth #2035

----------------------------------------------------------------------------
Date Time Topic Speaker
----------------------------------------------------------------------------
Saturday, 11:00 am Simple ways to increase your aesthetic IF Marketing
March 2, business
2013
-----------------------------------------------------------------
1:00 pm New transdermal concepts with the Jill Waibel,
UltraPulse(R) M.D.
-----------------------------------------------------------------
2:00 pm Implementing VaserShape(R) into your Michael
practice Gold, M.D.
-----------------------------------------------------------------
3:00 pm ResurFX(TM) - Adding true functional non- Arielle N.B.
ablative resurfacing to a multi- Kauvar, M.D.
application platform
-----------------------------------------------------------------
4:00 pm Expand your practice with AcuPulse(TM) Girish
Munavalli,
M.D.
----------------------------------------------------------------------------
Sunday, 11:00 am Simple ways to increase your aesthetic IF Marketing
March 3, business
2013
-----------------------------------------------------------------
1:00 pm Clinical and molecular effects on mature David Ozog,
burn scars after treatment with a M.D.
fractional CO2 laser
-----------------------------------------------------------------
2:00 pm How to pick the right laser hair removal Rafael
system for your practice Nunes, M.D.
-----------------------------------------------------------------
3:00 pm Treating skin of color with the AcuPulse(TM) Michael
Gold, M.D.
-----------------------------------------------------------------
4:00 pm How laser hair removal keeps a practice Girish
thriving Munavalli,
M.D.
----------------------------------------------------------------------------
Monday, 11:00 am Simple ways to increase your aesthetic IF Marketing
March 4, business
2013
-----------------------------------------------------------------
2:00 pm M22's ResurFX(TM) - The next generation in Mitch
non-ablative fractional resurfacing Goldman,
M.D.
-----------------------------------------------------------------
2:30 pm The impact of laser scar revision on Nathan
wounded warriors Uebelhoer,
M.D.
----------------------------------------------------------------------------

Lumenis will also host a Clinical Symposium entitled "Versatility
Drives Patient and Practice Outcomes" on March 2 at 7pm at the Hilton
Bentley South Beach, 101 Ocean Drive, Miami Beach. The content will focus
on how dermatology practices can be transformed via UltraPulse(R) SCAAR
FX(TM), M22 with ResurFX(TM) module, QX Max and VaserShape(R). The
session will feature presentations and panel discussions with Mitch
Goldman, M.D., Mark Taylor, M.D., Jill Waibel, M.D. and Michael Gold,
M.D.

To celebrate the company's 45-year partnership with the physician
community and sales of over 80,000 medical lasers, Lumenis will also host
celebrations at its booth for the final hour of the exhibit schedule on
March 2 and 3.

About Lumenis

Lumenis, the world's largest medical laser company, is a global
developer, manufacturer and distributor of laser and light-based devices
for surgical, aesthetic and ophthalmic applications, with more than 900
employees worldwide. Lumenis has 265 registered patents, over 260 FDA
clearances, an installed base of over 80,000 systems and a presence in
over 80 countries. Lumenis endeavors to bring the finest state of the art
technology products to the market, fulfilling the highest standards of
excellence, quality and reliability, delivering premium value and service
to its customers. The name Lumenis is derived from the Latin words
meaning "Light of Life" highlighting the light -- the basis of our
technologies -- used to enhance life.

For more information about Lumenis and its products, please visit:
www.lumenis.com.

CoolScan(TM), Optimal Pulse Technology(TM), ResurFX(TM), UltraPulse(R),
SCAAR FX(TM), Lumenis(R) and the Lumenis logo are trademarks or
registered trademarks of Lumenis, Ltd.

VaserShape(R) is a registered trademark of Sound Surgical Technologies,
LLC.

*The ResurFX module of M22 is available in the U.S. pending U.S. Food and
Drug Administration (FDA) clearance.

For further information contact:

Jeff Jacomowitz
Lazar Partners Ltd.
(212) 867 1762
jjacomowitz@lazarpartners.com

Copyright 2013, Marketwire, All rights reserved.

-0-